Risky business: Rx drugs obtained in the secondary market

Michael Hegener, PharmD, BCACP, discusses how workforce development can best address the evolving knowledge, skills, and abilities needed in community pharmacy practice.

As artificial intelligence evolves from a novel technology to commonplace in health care, the pharmacy industry is adapting to its challenges and opportunities.

Mitchell Barnett, PharmD, MS, discusses what lessons can be learned from a community pharmacy drug disposal program.

From market pressures to regulatory framework, Eric Tichy, PharmD, MBA, BCPS, FCCP, FAST, discussed growth in the business of health-system pharmacy and the challenges it has faced.

Douglas Hoey, CEO of NCPA, discusses what independent pharmacies can do to handle an influx of patients and what the chain’s situation means for the pharmacy landscape.

Fitusiran (Qfitlia) is approved for patients 12 years and older with or without factor VIII or IX inhibitors.